Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OSIMERTINIB Cause Cardiac failure congestive? 85 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 85 reports of Cardiac failure congestive have been filed in association with OSIMERTINIB (TAGRISSO). This represents 0.3% of all adverse event reports for OSIMERTINIB.

85
Reports of Cardiac failure congestive with OSIMERTINIB
0.3%
of all OSIMERTINIB reports
18
Deaths
52
Hospitalizations

How Dangerous Is Cardiac failure congestive From OSIMERTINIB?

Of the 85 reports, 18 (21.2%) resulted in death, 52 (61.2%) required hospitalization, and 8 (9.4%) were considered life-threatening.

Is Cardiac failure congestive Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OSIMERTINIB. However, 85 reports have been filed with the FAERS database.

What Other Side Effects Does OSIMERTINIB Cause?

Death (10,423) Malignant neoplasm progression (2,920) Diarrhoea (1,408) Drug resistance (1,026) Fatigue (819) Rash (772) Decreased appetite (706) Drug ineffective (627) Dyspnoea (621) Nausea (610)

What Other Drugs Cause Cardiac failure congestive?

ROSIGLITAZONE (15,085) METFORMIN\ROSIGLITAZONE (1,408) LENALIDOMIDE (1,373) AMBRISENTAN (1,359) SACUBITRIL\VALSARTAN (1,355) APIXABAN (1,144) CALCIUM\DEXTROSE\MAGNESIUM\SODIUM\SODIUM (1,129) AVANDIA (1,102) ADALIMUMAB (990) MACITENTAN (979)

Which OSIMERTINIB Alternatives Have Lower Cardiac failure congestive Risk?

OSIMERTINIB vs OSPEMIFENE OSIMERTINIB vs OSPHENA OSIMERTINIB vs OVINE DIGOXIN IMMUNE FAB OSIMERTINIB vs OXACILLIN OSIMERTINIB vs OXALIPLATIN

Related Pages

OSIMERTINIB Full Profile All Cardiac failure congestive Reports All Drugs Causing Cardiac failure congestive OSIMERTINIB Demographics